The anti-proliferative activity of metformin in several cancers is at least in part attributed to its ability to reduce the levels of insulin/IGF1, which in turn inhibits the insulin/IGF1 mediated molecular pathways that support tumor initiation and progression rather than a direct anti-proliferative/anti-cancer action (Figure 2) [44]. The gene discussed is INS; the disease is cancer.